نتایج جستجو برای: dasatinib

تعداد نتایج: 1954  

2017
Yoritake Sakoda Yojiro Arimori Masakatsu Ueno Takafumi Matsumoto

A 39-year-old man treated with dasatinib for chronic myelogenous leukaemia presented to our hospital with haemoptysis, coughing, and dyspnoea. Chest radiography and computed tomography revealed ground-glass opacities and a crazy-paving pattern. Bronchoalveolar lavage was not performed due to serious hypoxemia and bleeding. Significant bleeding from the peripheral bronchi led to a diagnosis of a...

Journal: :Reactions Weekly 2021

Journal: :Blood 2008
Aditya Veldurthy Michaela Patz Susanne Hagist Christian P Pallasch Clemens-Martin Wendtner Michael Hallek Günter Krause

Src family kinases (SFKs) were described to be overexpressed in chronic lymphocytic leukemia (CLL). We wished to examine the effects of the Src and Abl kinase inhibitor dasatinib on the intracellular signaling and survival of CLL cells. Dasa-tinib showed a dose- and time-dependent reduction of global tyrosine phosphorylation and of activating phosphotyrosine levels of SFKs. Treatment with 100 n...

Journal: :Chemical & pharmaceutical bulletin 2013
Fei Liu Li-Wei Lang Ji Jiang Hua-Jun Lu Jian-Min Wang Shih-Chen Wang

Dasatinib was identified as a potent orally administered Src/Abl kinase inhibitor with excellent antiproliferative activity against Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. The low bioavailability of Dasatinib may be due to both incomplete oral absorption and first-pass metabolism. A prodrug, JLTN, was synthesized to minimize the first-pass effect of Dasat...

Journal: :Blood 2008
Athina Giannoudis Andrea Davies Claire M Lucas Robert J Harris Munir Pirmohamed Richard E Clark

We have previously shown that imatinib uptake into chronic myeloid leukemia (CML) cells is dependent on human organic cation transporter 1 (hOCT1; SLC22A1), and that low hOCT1 expression is an important determinant of clinical outcome to imatinib treatment. We hypothesized that dasatinib might be transported differently than imatinib, possibly accounting for its favorable effects in imatinib-re...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
M N Fornier P G Morris A Abbruzzi G D'Andrea T Gilewski J Bromberg C Dang M Dickler S Modi A D Seidman N Sklarin J Chang L Norton C A Hudis

BACKGROUND SRC plays an important role in the pathogenesis of metastatic breast cancer (MBC). In preclinical models, paclitaxel and the oral SRC inhibitor dasatinib showed greater antitumor activity than either agent. To determine the maximum tolerated dose of this combination, we conducted a phase I study. PATIENTS AND METHODS Patients with MBC; Eastern Cooperative Oncology Group performance...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2017
Anna Kreutzman Beatriz Colom-Fernández Ana Marcos Jiménez Mette Ilander Carlos Cuesta-Mateos Yaiza Pérez-García Cristina Delgado Arévalo Oscar Brück Henna Hakanen Jani Saarela Alvaro Ortega-Carrión Ana de Rosendo Alba Juanes-García Juan Luis Steegmann Satu Mustjoki Miguel Vicente-Manzanares Cecilia Muñoz-Calleja

Purpose: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, patients taking dasatinib often display severe adverse effects, including pleural effusions and increased risk of bleeding primarily in the gastrointestinal tract. The actual causes of these side effects are currently unde...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2008
Lisa J Christopher Donghui Cui Chiyuan Wu Roger Luo James A Manning Samuel J Bonacorsi Michael Lago Alban Allentoff Francis Y F Lee Betty McCann Susan Galbraith Donald P Reitberg Kan He Anthony Barros Anne Blackwood-Chirchir W Griffith Humphreys Ramaswamy A Iyer

SPRYCEL (dasatinib, BMS-354825; Bristol-Myers Squibb, Princeton, NJ), a multiple kinase inhibitor, is currently approved to treat chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia tumors in patients who are resistant or intolerant to imatinib mesylate (Gleevec; Novartis, Basel, Switzerland). After a 100-mg single p.o. dose of [(14)C]dasatinib to heal...

2012
Alison M. McCaig Emilio Cosimo Michael T. Leach Alison M. Michie

Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling pathways has become a novel therapeutic approach in CLL. The tyrosine kinase inhibitor dasatinib inhibits migration of several cell lines from soli...

2017
Andris Skride Matiss Sablinskis Kristaps Sablinskis Krista Lesina Aivars Lejnieks Sandra Lejniece

BACKGROUND There have been several reports on dasatinib-induced reversible pulmonary hypertension. This is the first reported case in Latvia; the patient did not discontinue the drug after the first adverse effects in the form of pleural effusions, which we speculate led only to partial reversion of the disease. CASE PRESENTATION A 67-year-old white man with chronic myelogenous leukemia was t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید